Plasmid selection in Escherichia coli using an endogenous essential gene marker

BMC Biotechnology

Volumn 8, Issue , 2008, Pages

  Goh, Shan ^a   Good, Liam ^a,b  

^a KAROLINSKA INSTITUTE   (Sweden)

^b ROYAL VETERINARY COLLEGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIOLOGY; CLONING; COMPUTER NETWORKS; ESCHERICHIA COLI; GENES; GENETIC ENGINEERING; GROWTH KINETICS; SYSTEM STABILITY; TOXIC MATERIALS; WATER POLLUTION;

TRICLOSAN;

CELL GROWTH;

AMPICILLIN; ENOYL ACYL CARRIER PROTEIN REDUCTASE (NADH); TRICLOSAN; ANTIINFECTIVE AGENT; BACTERIAL DNA; ESCHERICHIA COLI PROTEIN; FABI PROTEIN, E COLI;

ANTIBIOTIC RESISTANCE; ARTICLE; CELL GROWTH; CONTROLLED STUDY; ESCHERICHIA COLI; GENE INTERACTION; GENE OVEREXPRESSION; MARKER GENE; MOLECULAR CLONING; NONHUMAN; PLASMID; BACTERIAL GENE; BACTERIUM TRANSFORMATION; DRUG EFFECT; ESSENTIAL GENE; GENE EXPRESSION REGULATION; GENE VECTOR; GENETIC SELECTION; GENETICS; GROWTH, DEVELOPMENT AND AGING; MICROBIAL VIABILITY;

ESCHERICHIA COLI;

ANTI-BACTERIAL AGENTS; DNA, BACTERIAL; DRUG RESISTANCE, BACTERIAL; ENOYL-(ACYL-CARRIER-PROTEIN) REDUCTASE (NADH); ESCHERICHIA COLI; ESCHERICHIA COLI PROTEINS; GENE EXPRESSION REGULATION, BACTERIAL; GENES, BACTERIAL; GENES, ESSENTIAL; GENETIC VECTORS; MICROBIAL VIABILITY; PLASMIDS; SELECTION (GENETICS); TRANSFORMATION, BACTERIAL; TRICLOSAN;

EID: 50849136499     PISSN: None     EISSN: 14726750     Source Type: Journal    
DOI: 10.1186/1472-6750-8-61     Document Type: Article

References (51)

1. Points to consider in the production and testing of new drugs and biologicals produced by recombinant DNA technology http://www.fda.gov/ cber/gdlns/ptcdna.htm
2. Validation of growth-based rapid microbiological methods for sterility testing of cellular and gene therapy products http://www.fda.gov/cber/ gdlns/stercgtp.htm
3. Titball RW Sjostedt A Pavelka MS Jr Nano FE Biosafety and selectable markers Ann N Y Acad Sci 2007, 1105:405-417. 10.1196/annals.1409.002 17416926
4. Fajardo A Martinez-Martin N Mercadillo M Galan JC Ghysels B Matthijs S Cornelis P Wiehlmann L Tummler B Baquero F Martinez JL The neglected intrinsic resistome of bacterial pathogens PLoS ONE 2008, 3:e1619. 2238818 18286176 10.1371/journal.pone.0001619
5. Gonzalez A Davila G Calva E Cloning of a DNA sequence that complements glutamine auxotrophy in Saccharomyces cerevisiae Gene 1985, 36:123-129. 10.1016/0378-1119(85)90076-9 2866146
6. Cranenburgh RM Hanak JA Williams SG Sherratt DJ Escherichia coli strains that allow antibiotic-free plasmid selection and maintenance by repressor titration Nucleic Acids Res 2001, 29:E26. 29739 11222777 10.1093/nar/29.5.e26
7. Dryselius R Nekhotiaeva N Nielsen PE Good L Antibiotic-free bacterial strain selection using antisense peptide nucleic acid Biotechniques 2003, 35:1060-1064. 14628680
8. Mairhofer J Pfaffenzeller I Merz D Grabherr R A novel antibiotic free plasmid selection system: Advances in safe and efficient DNA therapy Biotechnol J 2008, 3:83-89. 10.1002/biot.200700141 17806101
9. Xu HH Real L Bailey MW An array of Escherichia coli clones over-expressing essential proteins: A new strategy of identifying cellular targets of potent antibacterial compounds Biochem Biophys Res Commun 2006, 349:1250-1257. 10.1016/j.bbrc.2006.08.166 16978582
10. Bergler H Wallner P Ebeling A Leitinger B Fuchsbichler S Aschauer H Kollenz G Hogenauer G Turnowsky F Protein EnvM is the NADH-dependent enoyl-ACP reductase (FabI) of Escherichia coli J Biol Chem 1994, 269:5493-5496. 8119879
11. Heath RJ Yu YT Shapiro MA Olson E Rock CO Broad spectrum antimicrobial biocides target the FabI component of fatty acid synthesis J Biol Chem 1998, 273:30316-30320. 10.1074/jbc.273.46.30316 9804793
12. McMurry LM Oethinger M Levy SB Triclosan targets lipid synthesis Nature 1998, 394:531-532 10.1038/28970 9707111
13. Heath RJ Rubin JR Holland DR Zhang E Snow ME Rock CO Mechanism of triclosan inhibition of bacterial fatty acid synthesis J Biol Chem 1999, 274:11110-11114. 10.1074/jbc.274.16.11110 10196195
14. Russell AD Biocide use and antibiotic resistance: The relevance of laboratory findings to clinical and environmental situations Lancet Infect Dis 2003, 3:794-803. 10.1016/S1473-3099(03)00833-8 14652205
15. Panagakos FS Volpe AR Petrone ME DeVizio W Davies RM Proskin HM Advanced oral antibacterial/anti-inflammatory technology: A comprehensive review of the clinical benefits of a triclosan/copolymer/fluoride dentifrice J Clin Dent 2005, 16(Suppl):S1-19. 16583598
16. Wohlrab J Jost G Abeck D Antiseptic efficacy of a low-dosed topical triclosan/chlorhexidine combination therapy in atopic dermatitis Skin Pharmacol Physiol 2007, 20:71-76. 10.1159/000097653 17143011
17. Aiello AE Larson E Antibacterial cleaning and hygiene products as an emerging risk factor for antibiotic resistance in the community Lancet Infect Dis 2003, 3:501-506. 10.1016/S1473-3099(03)00723-0 12901892
18. Chuanchuen R Beinlich K Hoang TT Becher A Karkhoff-Schweizer RR Schweizer HP Cross-resistance between triclosan and antibiotics in Pseudomonas aeruginosa is mediated by multidrug efflux pumps: Exposure of a susceptible mutant strain to triclosan selects nfxB mutants overexpressing MexCD-OprJ Antimicrob Agents Chemother 2001, 45:428-432 90308 11158736 10.1128/AAC.45.2.428-432.2001
19. Braoudaki M Hilton AC Adaptive resistance to biocides in Salmonella enterica and Escherichia coli O157 and cross-resistance to antimicrobial agents J Clin Microbiol 2004, 42:73-78. 321691 14715734 10.1128/ JCM.42.1.73-78.2004
20. Karatzas KA Webber MA Jorgensen F Woodward MJ Piddock LJ Humphrey TJ Prolonged treatment of Salmonella enterica serovar Typhimurium with commercial disinfectants selects for multiple antibiotic resistance, increased efflux and reduced invasiveness J Antimicrob Chemother 2007, 60:947-955. 10.1093/jac/dkm314 17855722
21. Cole EC Addison RM Rubino JR Leese KE Dulaney PD Newell MS Wilkins J Gaber DJ Wineinger T Criger DA Investigation of antibiotic and antibacterial agent cross-resistance in target bacteria from homes of antibacterial product users and nonusers J Appl Microbiol 2003, 95:664-676. 10.1046/j.1365-2672.2003.02022.x 12969278
22. McBain AJ Bartolo RG Catrenich CE Charbonneau D Ledder RG Price BB Gilbert P Exposure of sink drain microcosms to triclosan: Population dynamics and antimicrobial susceptibility Appl Environ Microbiol 2003, 69:5433-5442. 194980 12957932 10.1128/AEM.69.9.5433-5442.2003
23. Beier RC Duke SE Ziprin RL Harvey RB Hume ME Poole TL Scott HM Highfield LD Alali WQ Andrews K Antibiotic and Disinfectant Susceptibility Profiles of Vancomycin-Resistant Enterococcus faecium (VRE) Isolated from Community Wastewater in Texas Bull Environ Contam Toxicol 2008
24. Opinion on triclosan resistance http://www.europa.eu.int/comm/food/fs/sc/ ssc/out269_en.pdf
25. Drug approvals http://www.fda.gov/cder/da/da1201.htm
26. Lee C Kim J Shin SG Hwang S Absolute and relative QPCR quantification of plasmid copy number in Escherichia coli J Biotechnol 2006, 123:273-280. 10.1016/j.jbiotec.2005.11.014 16388869
27. Livak KJ Schmittgen TD Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method Methods 2001, 25:402-408. 10.1006/meth.2001.1262 11846609
28. Nilsson AI Zorzet A Kanth A Dahlstrom S Berg OG Andersson DI Reducing the fitness cost of antibiotic resistance by amplification of initiator tRNA genes Proc Natl Acad Sci USA 2006, 103:6976-6981. 1459004 16636273 10.1073/pnas.0602171103
29. Roth BL Poot M Yue ST Millard PJ Bacterial viability and antibiotic susceptibility testing with SYTOX green nucleic acid stain Appl Environ Microbiol 1997, 63:2421-2431. 168536 9172364
30. Lenski RE Simpson SC Nguyen TT Genetic analysis of a plasmid-encoded, host genotype-specific enhancement of bacterial fitness J Bacteriol 1994, 176:3140-3147. 205481 8195066
31. Guzman LM Belin D Carson MJ Beckwith J Tight regulation, modulation, and high-level expression by vectors containing the arabinose PBAD promoter J Bacteriol 1995, 177:4121-4130. 177145 7608087
32. Heath RJ Rock CO Regulation of fatty acid elongation and initiation by acyl-acyl carrier protein in Escherichia coli J Biol Chem 1996, 271:1833-1836. 10.1074/jbc.271.4.1833 8567624
33. Ward WH Holdgate GA Rowsell S McLean EG Pauptit RA Clayton E Nichols WW Colls JG Minshull CA Jude DA Kinetic and structural characteristics of the inhibition of enoyl (acyl carrier protein) reductase by triclosan Biochemistry 1999, 38:12514-12525 10.1021/bi9907779 10493822
34. Weitao T Nordstrom K Dasgupta S Mutual suppression of mukB and seqA phenotypes might arise from their opposing influences on the Escherichia coli nucleoid structure Mol Microbiol 1999, 34:157-168. 10.1046/ j.1365-2958.1999.01589.x 10540294
35. Yue TF Dayton PG Gutman AB Mutual Suppression of the Uricosuric Effects of Sulfinpyrazone and Salicylate: A Study in Interactions between Drugs J Clin Invest 1963, 42:1330-1339. 289403 14060403 10.1172/JCI104817
36. Wild DG Reversion from erythromycin dependence in Escherichia coli: strains altered in ribosomal sub-unit association and ribosome assembly J Gen Microbiol 1988, 134:1251-1263. 2462010
37. Goldstein F Perutka J Cuirolo A Plata K Faccone D Morris J Sournia A Kitzis MD Ly A Archer G Rosato AE Identification and phenotypic characterization of a beta-lactam-dependent, methicillin-resistant Staphylococcus aureus strain Antimicrob Agents Chemother 2007, 51:2514-2522. 1913265 17470657 10.1128/AAC.00040-07
38. Van Bambeke F Chauvel M Reynolds PE Fraimow HS Courvalin P Vancomycin-dependent Enterococcus faecalis clinical isolates and revertant mutants Antimicrob Agents Chemother 1999, 43:41-47. 89018 9869563
39. Aiello AE Marshall B Levy SB Della-Latta P Larson E Relationship between triclosan and susceptibilities of bacteria isolated from hands in the community Antimicrob Agents Chemother 2004, 48:2973-2979. 478530 15273108 10.1128/AAC.48.8.2973-2979.2004
40. Gilbert P McBain A Sreenivasan P Common therapeutic approaches for the control of oral biofilms: Microbiological safety and efficacy Clin Microbiol Infect 2007, 13(Suppl 4):17-24. 10.1111/ j.1469-0691.2007.01800.x 17716292
41. Orvos DR Versteeg DJ Inauen J Capdevielle M Rothenstein A Cunningham V Aquatic toxicity of triclosan Environ Toxicol Chem 2002, 21:1338-1349. 10.1897/1551-5028(2002)021<1338:ATOT>2.0.CO;2 12109732
42. Federle TW Kaiser SK Nuck BA Fate and effects of triclosan in activated sludge Environ Toxicol Chem 2002, 21:1330-1337. 10.1897/ 1551-5028(2002)021<1330:FAEOTI>2.0.CO;2 12109731
43. Aranami K Readman JW Photolytic degradation of triclosan in freshwater and seawater Chemosphere 2007, 66:1052-1056. 10.1016/ j.chemosphere.2006.07.010 16930676
44. Keating DH Carey MR Cronan JE Jr The unmodified (apo) form of Escherichia coli acyl carrier protein is a potent inhibitor of cell growth J Biol Chem 1995, 270:22229-22235. 10.1074/jbc.270.38.22229 7673201
45. Subrahmanyam S Cronan JE Jr Overproduction of a functional fatty acid biosynthetic enzyme blocks fatty acid synthesis in Escherichia coli J Bacteriol 1998, 180:4596-4602 107473 9721301
46. Heath RJ Li J Roland GE Rock CO Inhibition of the Staphylococcus aureus NADPH-dependent enoyl-acyl carrier protein reductase by triclosan and hexachlorophene J Biol Chem 2000, 275:4654-4659. 10.1074/jbc.275.7.4654 10671494
47. McMurry LM McDermott PF Levy SB Genetic evidence that InhA of Mycobacterium smegmatis is a target for triclosan Antimicrob Agents Chemother 1999, 43:711-713 89191. 10049298
48. Heerding DA Chan G DeWolf WE Fosberry AP Janson CA Jaworski DD McManus E Miller WH Moore TD Payne DJ 1,4-Disubstituted imidazoles are potential antibacterial agents functioning as inhibitors of enoyl acyl carrier protein reductase (FabI) Bioorg Med Chem Lett 2001, 11:2061-2065. 10.1016/S0960-894X(01)00404-8 11514139
49. Lu H Tonge PJ Inhibitors of FabI, an Enzyme Drug Target in the Bacterial Fatty Acid Biosynthesis Pathway Acc Chem Res 2008, 41:11-20. 10.1021/ ar700156e 18193820
50. Heath RJ Rock CO A triclosan-resistant bacterial enzyme Nature 2000, 406:145-146. 10.1038/35022656 10910344
51. Marrakchi H Dewolf WE Jr Quinn C West J Polizzi BJ So CY Holmes DJ Reed SL Heath RJ Payne DJ Characterization of Streptococcus pneumoniae enoyl-(acyl-carrier protein) reductase (FabK) Biochem J 2003, 370:1055-1062. 1223239 12487627 10.1042/BJ20021699